Acute onset of fingolimod-associated macular edema

PURPOSE: Fingolimod is among the first oral disease-modifying agents for the treatment of relapsing-remitting multiple sclerosis (MS). Despite its favorable safety profile, fingolimod may cause macular edema, a significant adverse event, which occurs within the first 4 months of therapy. Macular ede...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Am J Ophthalmol Case Rep
Auteurs principaux: Soliman, Mohamed Kamel, Sarwar, Salman, Sadiq, Mohammad A., Jack, Loren, Jouvenat, Neil, Zabad, Rana K., Kedar, Sachin, Nguyen, Quan Dong
Format: Artigo
Langue:Inglês
Publié: Elsevier 2016
Sujets:
Case report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5757484/
https://ncbi.nlm.nih.gov/pubmed/29503930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajoc.2016.09.005
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires